The acquisition, whose deal value was not disclosed, would give Ocimum Biosolutions, a provider of laboratory information management systems (LIMS), bioinformatics solutions, Microarrays and contract research the opportunity to become a global oligo player, according to Ms Anuradha Acharya, its CEO.
"We will continue looking for targets in related areas to scale up our oligo production capability. This acquisition will also help us become a more integrated genomics services provider with three delivery points in Indianapolis, Ijsselstein (Netherlands) and Hyderabad," she said.
Mr Hans Beijersbergen van Henegouwen, MD of Isogen Life Science, said, "The new business configuration will be much more flexible and will be able to play an important role in the vast growing demand for oligo nucleotides all over the world."
Avendus Advisors was the sole financial advisor to Ocimum for the deal.
Acquisition route
Ocimum has, in the recent past, used the acquisition route to scale up, the German MWG Biotech's division being one example, according to a company press release here.
Isogen Life Science is a leading supplier of products for the life science sector. The company provides a wide range of instruments, reagents and consumables in the areas of cell biology, molecular biology and biochemistry.
Oligo nucleotides are basic material used widely in molecular biology laboratories across the world. They are used in gene sequencing studies, micro-arrays and have an important role in better understanding of genes.
Vassiliou welcomes entry into force of ban on imports, exports and trade in cat and dog fur